165 related articles for article (PubMed ID: 23927471)
1. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.
Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ
J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471
[TBL] [Abstract][Full Text] [Related]
2. Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.
Kaur I; Kosak KM; Terrazas M; Herron JN; Kern SE; Boucher KM; Shami PJ
Pharm Res; 2015 Apr; 32(4):1395-406. PubMed ID: 25330743
[TBL] [Abstract][Full Text] [Related]
3. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
[TBL] [Abstract][Full Text] [Related]
5. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
Sjödin B; Mannervik B
Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
[TBL] [Abstract][Full Text] [Related]
6. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
Udupi V; Yu M; Malaviya S; Saavedra JE; Shami PJ
Leuk Res; 2006 Oct; 30(10):1279-83. PubMed ID: 16439016
[TBL] [Abstract][Full Text] [Related]
7. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
[TBL] [Abstract][Full Text] [Related]
10. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
Simeone AM; McMurtry V; Nieves-Alicea R; Saavedra JE; Keefer LK; Johnson MM; Tari AM
Breast Cancer Res; 2008; 10(3):R44. PubMed ID: 18474097
[TBL] [Abstract][Full Text] [Related]
11. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.
Heckler M; Osterberg N; Guenzle J; Thiede-Stan NK; Reichardt W; Weidensteiner C; Saavedra JE; Weyerbrock A
Tumour Biol; 2017 Jun; 39(6):1010428317703922. PubMed ID: 28653883
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
Kumar V; Hong SY; Maciag AE; Saavedra JE; Adamson DH; Prud'homme RK; Keefer LK; Chakrapani H
Mol Pharm; 2010 Feb; 7(1):291-8. PubMed ID: 20000791
[TBL] [Abstract][Full Text] [Related]
13. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
Shami PJ; Maciag AE; Eddington JK; Udupi V; Kosak KM; Saavedra JE; Keefer LK
Leuk Res; 2009 Nov; 33(11):1525-9. PubMed ID: 19193435
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.
Shami PJ; Saavedra JE; Bonifant CL; Chu J; Udupi V; Malaviya S; Carr BI; Kar S; Wang M; Jia L; Ji X; Keefer LK
J Med Chem; 2006 Jul; 49(14):4356-66. PubMed ID: 16821795
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
Nandurdikar RS; Maciag AE; Citro ML; Shami PJ; Keefer LK; Saavedra JE; Chakrapani H
Bioorg Med Chem Lett; 2009 May; 19(10):2760-2. PubMed ID: 19364650
[TBL] [Abstract][Full Text] [Related]
16. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
17. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
Kiziltepe T; Anderson KC; Kutok JL; Jia L; Boucher KM; Saavedra JE; Keefer LK; Shami PJ
J Pharm Pharmacol; 2010 Jan; 62(1):145-51. PubMed ID: 20723011
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
Liu J; Li C; Qu W; Leslie E; Bonifant CL; Buzard GS; Saavedra JE; Keefer LK; Waalkes MP
Mol Cancer Ther; 2004 Jun; 3(6):709-14. PubMed ID: 15210857
[TBL] [Abstract][Full Text] [Related]
19. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
[TBL] [Abstract][Full Text] [Related]
20. JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca
Huang Z; Liu L; Chen J; Cao M; Wang J
Biomed Pharmacother; 2018 Nov; 107():1385-1392. PubMed ID: 30257354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
